NASDAQ · Biotechnology

OBIO (OBIO) Stock

$3.86 +1.05% NASDAQ: OBIO Healthcare

Valuation

MetricValue
Price$3.86
Market Cap$231.14M
P/E Ratio-3.70
P/B Ratio3.91
P/S Ratio6.81
EPS (TTM)$-1.11
52-Week High$5.42
52-Week Low$2.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-84.13%
ROA-46.09%
ROCE-81.25%
Gross Margin-157.58%
Operating Margin-157.58%
Net Margin-1.67%
Debt/Equity0.03
Current Ratio6.35

Annual Financials (USD)

Metric20212022202320242025
Revenue$-1.0M$4.0M$3.0M$3.0M$33.0M
Operating Profit$-22.0M$-33.0M$-52.0M$-64.0M$-52.0M
Net Profit$-23.0M$-34.0M$-49.0M$-61.0M$-53.0M
EPS$-0.02$-1.32$-1.48$-1.66$-1.11
Op Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$14.0M$96.0M$95.0M$76.0M$115.0M
Total Liabilities$85.0M$43.0M$27.0M$43.0M$51.0M
Cash$10.0M$20.0M$31.0M$22.0M$35.0M
Borrowings$6.0M$12.0M$2.0M$17.0M$2.0M

Latest News

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes GlobeNewswire · Jun 29, 2026 Sidoti Events, LLC's June Small-Cap Virtual Conference ACCESS Newswire · Jun 16, 2026 Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 2, 2026 Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock Simply Wall St. · May 21, 2026 Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference GlobeNewswire · May 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-29.0M$-46.0M$-51.0M$-49.0M
Investing Cash Flow$13.0M$-65.0M$11.0M$13.0M$-27.0M
Financing Cash Flow$0$-10.0M$57.0M$-1.0M$-2.0M
Net Cash Flow$-10.0M$10.0M$11.0M$-8.0M$12.0M
Free Cash Flow$-20.0M$-30.0M$-46.0M$-51.0M$-49.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-24.72%
Quick Ratio7.01
Interest Coverage-52.00
Return 1Y14.11%
Return 3Y-50.00%
Return 5Y-63.28%

Ownership

Insiders Held24.57%
Institutions Held41.78%
Institutions Float Held55.38%
Institutional HolderSharesReport Date
RTW Investments LP8,306,0632026-03-31
Perceptive Advisors Llc5,037,9062026-03-31
Vanguard Capital Management LLC2,204,3192026-03-31
Alyeska Investment Group, L.p.1,000,0002026-03-31
Propel Bio Management, LLC896,7012026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVTX $18.97 +2.87% -2.79 $214.25M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
EPRX $6.05 +4.13% -5.99 $202.55M 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%

About OBIO

OBIO is led by CEO David Hochman, publicly traded since 2020.

OBIO stock trades at $3.86 with a market capitalization of $231.14M. The stock is valued at a price-to-earnings (P/E) ratio of -3.70, price-to-book of 3.91, price-to-sales of 6.81. Over the past 52 weeks the stock has ranged between $2.20 and $5.42, and currently trades 28.8% below its 52-week high.

On profitability, OBIO generates a return on equity (ROE) of -84.13%, return on capital employed of -81.25%, an operating margin of -157.58%, a net profit margin of -1.67%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides